Alto Neuroscience (NYSE:ANRO) Shares Down 5.5% – What’s Next?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) were down 5.5% during mid-day trading on Monday . The company traded as low as $26.37 and last traded at $26.0350. Approximately 270,408 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 363,358 shares. The stock had previously closed at $27.54.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ANRO shares. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. JonesTrading decreased their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Wedbush lifted their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Robert W. Baird reduced their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Wolfe Research assumed coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Trading Up 3.8%

The firm has a fifty day moving average of $23.25 and a two-hundred day moving average of $21.32. The company has a market cap of $943.57 million, a PE ratio of -11.11 and a beta of 1.04. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently made changes to their positions in the stock. Invesco Ltd. bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at $67,000. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the 1st quarter valued at about $52,000. Marshall Wace LLP increased its position in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after buying an additional 84,417 shares during the period. Jane Street Group LLC purchased a new stake in shares of Alto Neuroscience in the second quarter worth about $240,000. Finally, Bridgeway Capital Management LLC boosted its position in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.